Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC)versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8%) treated with nintedanib and 38 of 423 patients (9.0%) treated with placebo had an improvement/no decline in FVC in the INPULSIS® trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31–152) mL and 57.5 (31–103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS®-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS® trial. In the INPULSIS® trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationEfficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0562oc · Cited by 280
Self-citationEffect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Self-citationDaily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
Cited by
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Man, R. K., Gogikar, A., Nanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M., & Ramphall, S. (2024) · Cureus · doi:10.7759/cureus.54268 · Cited by 30
“…effects of antifibrotic medications in these patients, as well as issues with patients who are elderly and have accompanying comorbidities, doctors are still hesitant to treat patients with advanced IPF, even though nintedanib treatment results in a physiological improvement of lung function [14].”
BackgroundNishioka, Y., Homma, S., Ogura, T., Sato, S., Arai, N., Tomii, K., Kamio, K., Sakamoto, S., Miyazaki, Y., Tomioka, H., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.008 · Cited by 12
Metadata
- Authors
- Flaherty, K. R., Kolb, M., Vancheri, C., Tang, W., Conoscenti, C. S., & Richeldi, L.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2018-06-25
- Volume
- 52
- Issue
- 2
- Pages
- 1702593
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2811389906
- Cited by
- 43
- References
- 6
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/13993003.02593-2017
- The paper
- Flaherty, K. R., Kolb, M., Vancheri, C., Tang, W., Conoscenti, C. S., & Richeldi, L. (2018). Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.02593-2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.